Peripheral blood untargeted lipidomic profiling: Peripheral blood samples from cohort 1 will be analyzed using untargeted lipidomic profiling. No treatment or therapeutic intervention will be assigned by the investigators.
Peripheral blood targeted ceramide assay: Peripheral blood samples from cohort 2 will be analyzed using targeted ceramide assays. No treatment or therapeutic intervention will be assigned by the investigators.
Study summary
This prospective multi-cohort observational study evaluates the association between peripheral blood lipidomic and ceramide profiles and atrial fibrillation. The study hypothesis is that peripheral blood lipidomic features and ceramide-related profiles are associated with the presence of atrial fibrillation. Participants with atrial fibrillation and control participants with other cardiovascular diseases will be prospectively enrolled. Peripheral blood samples will be analyzed using untargeted lipidomic profiling in one cohort and targeted ceramide assays in another cohort.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adults aged 18 years or older.
* Participants who are able to provide informed consent.
* Participants diagnosed with atrial fibrillation based on Holter monitoring, or control participants with other cardiovascular diseases and no documented atrial fibrillation.
* Participants with available peripheral blood samples for untargeted lipidomic profiling or targeted ceramide analysis.
Exclusion Criteria:
* Inability or unwillingness to provide informed consent.
* Missing key clinical information.
* Missing or poor-quality peripheral blood samples unsuitable for lipidomic or targeted ceramide analysis.
* Participants considered unsuitable for this study by the investigators.
Primary outcome measure(s)
Peripheral Serum Concentration of Cer(d18:1/18:1), nmol/L — Baseline The concentration of Cer(d18:1/18:1) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/16:0), nmol/L — baseline The concentration of Cer(d18:1/16:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/18:0), nmol/L — Baseline The concentration of Cer(d18:1/18:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/20:0), nmol/L — Baseline The concentration of Cer(d18:1/20:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/22:0), nmol/L — Baseline The concentration of Cer(d18:1/22:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/24:0), nmol/L — Baseline The concentration of Cer(d18:1/24:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/24:1), nmol/L — Baseline The concentration of Cer(d18:1/24:1) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Normalized Relative Abundance of Serum Cer(d18:1/18:1), AU — Baseline The normalized relative abundance of Cer(d18:1/18:1) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU). Relative abundance will be compared between participants with atrial fibrillation and control participants.
Normalized Relative Abundance of Serum Cer(d18:1/16:0), AU — Baseline The normalized relative abundance of Cer(d18:1/16:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU). Relative abundance will be compared between participants with atrial fibrillation and control participants.
Normalized Relative Abundance of Serum Cer(d18:1/18:0), AU — Baseline The normalized relative abundance of Cer(d18:1/18:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU). Relative abundance will be compared between participants with atrial fibrillation and control participants.
Normalized Relative Abundance of Serum Cer(d18:1/20:0), AU — Baseline The normalized relative abundance of Cer(d18:1/20:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU). Relative abundance will be compared between participants with atrial fibrillation and control participants.
Normalized Relative Abundance of Serum Cer(d18:1/22:0), AU — Baseline The normalized relative abundance of Cer(d18:1/22:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU). Relative abundance will be compared between participants with atrial fibrillation and control participants.
Normalized Relative Abundance of Serum Cer(d18:1/24:0), AU — Baseline The normalized relative abundance of Cer(d18:1/24:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU). Relative abundance will be compared between participants with atrial fibrillation and control participants.
Normalized Relative Abundance of Serum Cer(d18:1/24:1), AU — Baseline The normalized relative abundance of Cer(d18:1/24:1) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU). Relative abundance will be compared between participants with atrial fibrillation and control participants.
Trial sites (1)
Facility
City
Region
Status
First Affiliated Hospital of Xian JiaotongUniversity
Xi'an
Shaanxi
Recruiting
More First Affiliated Hospital Xi'an Jiaotong University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.